Literature DB >> 14739777

MdmX represses E2F1 transactivation.

Mark Wunderlich1, Mithua Ghosh, Karen Weghorst, Steven J Berberich.   

Abstract

Based on knockout mouse studies, Mdm2 and MdmX have been identified as critical regulators of the p53 tumor suppressor protein, at least during early development. While many of the functions attributed to Mdm2 and MdmX involve p53 and overexpression of each gene appears to have oncogenic activities, a number of studies have suggested that each protein also possesses p53-independent functions. While examining the effect of Mdm2 overexpression on E2F1 transactivation we uncovered a novel MdmX function, the ability to inhibit E2F1 transactivation in a p53 and Mdm2 independent manner. Using a series of MdmX deletion mutants the central region of MdmX, amino acids 128-444 appears to possess the repressive domain. While an in vivo association of MdmX with either E2F1 or DP1 was not observed, a slight reduction in DP1 and an increased cytoplasmic localization of E2F1 were seen in cells overexpressing MdmX. These results suggest that elevated MdmX expression may repress E2F1-regulated genes like p14ARF and thus represent another regulatory mechanism in the Rb-p53 signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14739777

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  14 in total

1.  Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.

Authors:  Lan Cao; Ahmed Basudan; Matthew J Sikora; Amir Bahreini; Nilgun Tasdemir; Kevin M Levine; Rachel C Jankowitz; Priscilla F McAuliffe; David Dabbs; Sue Haupt; Ygal Haupt; Peter C Lucas; Adrian V Lee; Steffi Oesterreich; Jennifer M Atkinson
Journal:  Cancer Lett       Date:  2019-06-20       Impact factor: 8.679

Review 2.  p53 ubiquitination: Mdm2 and beyond.

Authors:  Christopher L Brooks; Wei Gu
Journal:  Mol Cell       Date:  2006-02-03       Impact factor: 17.970

3.  MDMX exerts its oncogenic activity via suppression of retinoblastoma protein.

Authors:  H Zhang; L Hu; W Qiu; T Deng; Y Zhang; J Bergholz; Z-X Xiao
Journal:  Oncogene       Date:  2015-02-23       Impact factor: 9.867

4.  MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53.

Authors:  Alyssa M Klein; Lynn Biderman; David Tong; Bita Alaghebandan; Sakina A Plumber; Helen S Mueller; Anne van Vlimmeren; Chen Katz; Carol Prives
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-02       Impact factor: 11.205

Review 5.  MdmX regulates transformation and chromosomal stability in p53-deficient cells.

Authors:  Zdenka Matijasevic; Anna Krzywicka-Racka; Greenfield Sluder; Stephen N Jones
Journal:  Cell Cycle       Date:  2008-10-15       Impact factor: 4.534

Review 6.  The Roles of MDM2 and MDMX in Cancer.

Authors:  Orit Karni-Schmidt; Maria Lokshin; Carol Prives
Journal:  Annu Rev Pathol       Date:  2016-03-17       Impact factor: 23.472

Review 7.  Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.

Authors:  Qin Li; Guillermina Lozano
Journal:  Clin Cancer Res       Date:  2012-12-21       Impact factor: 12.531

Review 8.  MDM2, MDMX and p53 in oncogenesis and cancer therapy.

Authors:  Mark Wade; Yao-Cheng Li; Geoffrey M Wahl
Journal:  Nat Rev Cancer       Date:  2013-01-10       Impact factor: 60.716

9.  High levels of Hdmx promote cell growth in a subset of uveal melanomas.

Authors:  Job de Lange; Amina Fas Teunisse; Matty Verlaan-de Vries; Kirsten Lodder; Suzanne Lam; Gregorius Pm Luyten; Federico Bernal; Martine J Jager; Aart G Jochemsen
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

10.  MDM4 (MDMX) and its Transcript Variants.

Authors:  F Mancini; G Di Conza; F Moretti
Journal:  Curr Genomics       Date:  2009-03       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.